Search Results

Dabrafenib 100 mg  | Purity Not Available

TargetMol

Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).

More Information Supplier Page

Rac-Belinostat 50 mg  | 99.93%

TargetMol

Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.

More Information Supplier Page

SB-431542 100 mg  | 99.87%

TargetMol

SB-431542(SB 431542) is a potent and selective inhibitor of ALK5 (IC50: 94 nM) and is also an inhibitor of ALK4 (IC50: 140 nM) and ALK7.

More Information Supplier Page

SB-431542 10 mg  | 99.87%

TargetMol

SB-431542(SB 431542) is a potent and selective inhibitor of ALK5 (IC50: 94 nM) and is also an inhibitor of ALK4 (IC50: 140 nM) and ALK7.

More Information Supplier Page

7ACC2 10 mg  | 100.00%

TargetMol

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.

More Information Supplier Page

7ACC2 2 mg  | 100.00%

TargetMol

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.

More Information Supplier Page